This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Faces Challenges

Can BMY develop or buy more "pearls" that it can add to its "string?" We might find out soon when the company presents at the Barclays 2013 Global Health Care Conference on Tuesday, March 12, in Miami.

Michael Giordano, senior vice president and head of Development, Oncology & Immunology, will make a formal presentation about the company at 9:30 a.m. ET. It would not surprise me to hear some encouraging news as to the BMY strategy going forward on filling its pipeline and at the very least sustaining the sales profits at the 2012 levels.

By the end of 2012 BMY had operating cash flow of nearly $7 billion and total cash (most recent quarter) of $2.83 billion. It can generate more revenue with wider distribution of Eliquis, which has been touted as a drug that can prevent strokes. It will be sold in partnership with Pfizer (PFE).

There are numerous other ways BMY can preserve and grow its triumphant share price including international sales expansions in areas like Asia. The challenges the world faces with diseases like hepatitis C are growing, and by some estimates could eventually present a $5 billion to $10 billion market if aggressively marketed.

In the meantime don't count out the possibility that BMY is already on the radar screen of some cashed-up predators that will pay dearly for its "string of pearls" including the ones in late-stage development.

At the time of publication the author had a position in PFE.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Make smarter trading decisions and provide investment ideas that could help make you richer. Bryan Ashenberg does the dirty work so you don't have to!
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $71.08 -0.10%
TSLA $214.81 1.60%
YHOO $37.22 0.76%
AAPL $92.59 -0.70%
FB $119.25 1.20%


Chart of I:DJI
DOW 17,715.47 +54.76 0.31%
S&P 500 2,054.55 +3.92 0.19%
NASDAQ 4,727.3670 +10.2730 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs